(Q40666915)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

review article

1 reference

title

Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

0 references

L S Schneider

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

P N Tariot

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

publication date

1 July 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

23 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

volume

78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

page(s)

911-934

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease

23 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Cholinomimetic treatment fails to improve memory disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Chelation therapy. Unproved modality in the treatment of Alzheimer-type dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Selective loss of central cholinergic neurons in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Induction of depression with oxotremorine in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Comparison of septo-hippocampal with basalo-cortical projection neurons in the rat: an electrophysiological approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Tacrine in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Memantine in the treatment of senile dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The viral hypothesis of Alzheimer's disease. Absence of antibodies to lentiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The effect of long-term physostigmine administration in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Multicenter trial of naloxone in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Effect of naltrexone on senile dementia of the Alzheimer type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The effect of ACTH4-9 analog (Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Alzheimer Disease: Basic and Clinical Advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Diagnosis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

K-252b selectively potentiates cellular actions and trk tyrosine phosphorylation mediated by neurotrophin-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Multiple nutrients in the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Brief information on an early phase-II study with deprenyl in demented patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Anti-inflammatory drugs and Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Intramuscular desferrioxamine in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Maintenance on L-deprenyl prolongs life in aged male rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

GABA-agonist therapy for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Clonidine treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Oral physostigmine treatment of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

No response to high-dose muscarinic agonist therapy in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Necropsy evidence of central cholinergic deficits in senile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Potential use of nerve growth factor to treat Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Bromocriptine in presenile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Prions and neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Clinical trial of indomethacin in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

A new rating scale for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Guanfacine treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

A pilot study of low-dose L-deprenyl in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Overview of clinical trials of hydergine in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Lack of effect of tryptophan treatment in demented gerontopsychiatric patients. A double-blind, crossover-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Effects of oral physostigmine in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Long-term administration of oral physostigmine in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

CERAD behavior rating scale for dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Naloxone and Alzheimer's disease. Cognitive and behavioral effects of a range of doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Multiple-dose arecoline infusions in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Memory Enhancement with Oral Physostigmine in Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The safety and lack of efficacy of vinpocetine in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Effect of deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The effect of sabeluzole (R 58735) on memory retrieval functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Major depression in primary dementia. Clinical and neuropathologic correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Neurochemical Correlates of Major Depression in Primary Dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

The neuropathology of aminergic nuclei in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930142-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(16)30142-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8022237%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference